EMT is associated with resistance to conventional cancer therapies, including chemotherapy and targeted therapies. The mesenchymal phenotype is often linked to the activation of survival pathways and the expression of drug efflux pumps, which contribute to therapeutic resistance. Understanding the mechanisms underlying EMT can help in the development of novel therapeutic strategies aimed at preventing or reversing EMT to improve treatment efficacy.
